clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lung Diseases D008171 37 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lymphadenitis D008199 8 associated lipids
Lymphangitis D008205 4 associated lipids
Mycetoma D008271 4 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Mastoiditis D008417 2 associated lipids
Metaplasia D008679 7 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Myocardial Infarction D009203 21 associated lipids
Myxoma D009232 1 associated lipids
Nasal Polyps D009298 26 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Nocardia Infections D009617 6 associated lipids
Endophthalmitis D009877 12 associated lipids
Psittacosis D009956 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Otitis Media D010033 12 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Pain D010146 64 associated lipids
Pancreatitis D010195 10 associated lipids
Parkinson Disease D010300 53 associated lipids
Paronychia D010304 3 associated lipids
Parotid Diseases D010305 1 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Parotitis D010309 4 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Periodontal Abscess D010508 2 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Pleural Diseases D010995 4 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Proteinuria D011507 30 associated lipids
Prurigo D011536 4 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Psoriasis D011565 47 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pyelonephritis D011704 5 associated lipids
Radiation Injuries D011832 14 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rickettsia Infections D012282 5 associated lipids
Rodent Diseases D012376 4 associated lipids
Rosacea D012393 13 associated lipids
Scrub Typhus D012612 3 associated lipids
Serositis D012700 1 associated lipids
Shock, Septic D012772 11 associated lipids
Sinusitis D012852 9 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Skin Neoplasms D012878 12 associated lipids
Skin Ulcer D012883 6 associated lipids
Splenic Diseases D013158 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Stomach Diseases D013272 7 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Synovitis D013585 15 associated lipids
Syphilis D013587 6 associated lipids
Tenosynovitis D013717 3 associated lipids
Tooth Discoloration D014075 7 associated lipids
Tuberculosis D014376 20 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Typhoid Fever D014435 2 associated lipids
Ureteral Diseases D014515 3 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Urethritis D014526 9 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urination Disorders D014555 9 associated lipids
Urticaria D014581 13 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Whooping Cough D014917 6 associated lipids
Wound Infection D014946 12 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Discitis D015299 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Eye Infections D015817 1 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Bacteremia D016470 9 associated lipids
Helicobacter Infections D016481 21 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Ednie LM et al. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). 1997 Antimicrob. Agents Chemother. pmid:9303406
Visalli MA et al. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. 1997 Antimicrob. Agents Chemother. pmid:9303375
Versalovic J et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. 1997 J. Antimicrob. Chemother. pmid:9301997
López-Brea M et al. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. 1997 J. Antimicrob. Chemother. pmid:9301996
Stone GG et al. PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial. 1997 J. Antimicrob. Chemother. pmid:9301991
Irie Y et al. Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. 1997 J. Antimicrob. Chemother. pmid:9301989
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. 1997 Gut pmid:9301496
Laberge P and Martineau P Clarithromycin-induced digoxin intoxication. 1997 Ann Pharmacother pmid:9296239
Recker MW and Kier KL Potential interaction between clarithromycin and warfarin. 1997 Ann Pharmacother pmid:9296238
Visalli MA et al. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. 1997 Diagn. Microbiol. Infect. Dis. pmid:9294703
Akaki T et al. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. 1997 Kekkaku pmid:9293712
Kearsley NL et al. Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children with pharyngitis and/or tonsillitis. 1997 Apr-May Br J Clin Pract pmid:9293051
Sekkarie MA Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. 1997 Am. J. Kidney Dis. pmid:9292575
Kobler E et al. [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. 1997 Schweiz Med Wochenschr Suppl pmid:9289833
Tan WC et al. Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis. 1997 Int. J. Clin. Pract. pmid:9287260
Matsukura N [Two step therapy for education of Helicobacter pylori]. 1997 Nihon Shokakibyo Gakkai Zasshi pmid:9284449
Hirakawa T [Diagnosis and treatment of Helicobacter pylori]. 1997 Nippon Ika Daigaku Zasshi pmid:9283206
Lam SK et al. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. 1997 Gut pmid:9274470
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. 1997 Gut pmid:9274464
Marone P et al. Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. 1997 J Chemother pmid:9269603
Uemura N et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. 1997 Cancer Epidemiol. Biomarkers Prev. pmid:9264278
Sato K et al. [Anti-Mycobacterium avium complex activities of KRM-1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages]. 1997 Kekkaku pmid:9259129
Shibata K et al. Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. 1997 Jpn J Antibiot pmid:9258741
Polis MA et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. 1997 Antimicrob. Agents Chemother. pmid:9257746
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Böttger EC et al. Prophylaxis of mycobacterial infection and acquired drug resistance. 1997 J. Antimicrob. Chemother. pmid:9249224
Fuursted K Evaluation of the post-antibiotic effect of six anti-mycobacterial agents against Mycobacterium avium by the Bactec radiometric method. 1997 J. Antimicrob. Chemother. pmid:9249202
Gisbert JP et al. Unhealed duodenal ulcers despite Helicobacter pylori eradication. 1997 Scand. J. Gastroenterol. pmid:9246702
Saluja A et al. A surgical wound infection due to Mycobacterium chelonae successfully treated with clarithromycin. 1997 Dermatol Surg pmid:9236871
Sano M et al. [A clinical study on combination therapy of antimicrobial agents for complicated urinary tract infection--with special reference to combination with clarithromycin]. 1997 Nippon Hinyokika Gakkai Zasshi pmid:9234616
Hoffman JS Pharmacological therapy of Helicobacter pylori infection. 1997 Semin. Gastrointest. Dis. pmid:9232728
Matsumoto T et al. Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. 1997 Lancet pmid:9228971
Svoboda P et al. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. 1997 May-Jun Hepatogastroenterology pmid:9222709
Gisbert JP et al. [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. 1997 Rev Esp Enferm Dig pmid:9221019
Nawarskas JJ et al. Digoxin toxicity secondary to clarithromycin therapy. 1997 Jul-Aug Ann Pharmacother pmid:9220047
Grunden JW and Fisher KA Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. 1997 Jul-Aug Ann Pharmacother pmid:9220046
Hoppe JE and Tschirner T Comparison of Etest and agar dilution for testing the activity of three macrolides against Bordetella parapertussis. 1997 Diagn. Microbiol. Infect. Dis. pmid:9218920
O'Brien B et al. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. 1997 May-Jun Can. J. Gastroenterol. pmid:9218858
Best LM et al. Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. 1997 May-Jun Can. J. Gastroenterol. pmid:9218854
Lim AG et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. 1997 Aliment. Pharmacol. Ther. pmid:9218079
Chimura T [Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection]. 1997 Jpn J Antibiot pmid:9212369
Meyer JM et al. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9210696
Mikasa K et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. 1997 Jul-Aug Chemotherapy pmid:9209786
Kim MJ et al. Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment. 1997 Gastroenterology pmid:9207259
Verhaegen J et al. Impredictable susceptibility for cephalosporins in penicillin resistant Streptococcus pneumoniae. 1997 Acta Clin Belg pmid:9204588
Götz JM et al. Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases. 1997 Gut pmid:9203935
Kato S et al. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. 1997 Pediatrics pmid:9200377
Marignani M et al. Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. 1997 Scand. J. Gastroenterol. pmid:9200297
Fréhel C et al. The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin. 1997 Infect. Immun. pmid:9199452
Lo WC et al. Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. 1997 Zhonghua Yi Xue Za Zhi (Taipei) pmid:9198292
Rubin BK et al. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. 1997 Am. J. Respir. Crit. Care Med. pmid:9196110
Gabl M et al. Flexor tenosynovitis in the hand caused by Mycobacterium malmoense: a case report. 1997 J Hand Surg Am pmid:9195437
Villanueva A et al. Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. 1997 Clin. Infect. Dis. pmid:9195073
Griffith DE Nontuberculous mycobacteria. 1997 Curr Opin Pulm Med pmid:9193860
Katari SR et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. 1997 Clin Transplant pmid:9193849
Waites K et al. In vitro activities of oral antimicrobial agents against penicillin-resistant Streptococcus pneumoniae: implications for outpatient treatment. 1997 South. Med. J. pmid:9191739
Ebell MH et al. Evaluation of the dyspeptic patient: a cost-utility study. 1997 J Fam Pract pmid:9191627
Damianos AJ and McGarrity TJ Treatment strategies for Helicobacter pylori infection. 1997 Am Fam Physician pmid:9191460
Gisbert JP et al. [One-week treatment with omeprazole, clarithromycin and amoxicillin: high efficacy in the eradication of Helicobacter pylori and cicatrization of duodenal ulcer]. 1997 Med Clin (Barc) pmid:9190436
Kadayifçi A et al. Clarithromycin-induced fever in a patient with Helicobacter pylori gastritis. 1997 Ann Pharmacother pmid:9184727
Pellegrin I et al. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. 1996 J. Antimicrob. Chemother. pmid:9182107
Langtry HD and Brogden RN Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. 1997 Drugs pmid:9179528
Nakao K et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. 1997 Am. J. Gastroenterol. pmid:9177520
Veldhuyzen van Zanten SJ et al. Helicobacter pylori: new developments and treatments. 1997 CMAJ pmid:9176424
Rodvold KA et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. 1997 Antimicrob. Agents Chemother. pmid:9174209
Tillenburg B et al. [Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)]. 1997 Z Gastroenterol pmid:9173687
Alfandari S et al. Isolated cutaneous Mycobacterium avium complex infection in AIDS. 1997 Int. J. Dermatol. pmid:9169332
OÄŸuz O et al. Conjunctival involvement in familial chronic benign pemphigus (Hailey-Hailey disease). 1997 Int. J. Dermatol. pmid:9169328
Walsh D et al. One week treatment for Helicobacter pylori infection. 1997 Arch. Dis. Child. pmid:9166031
Nilius AM et al. Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH. 1997 J. Clin. Microbiol. pmid:9163435
Peloquin CA and Berning SE Advice on treatment of Mycobacterium avium complex infection. 1997 Am J Health Syst Pharm pmid:9161632
Misiewicz JJ Management of Helicobacter pylori-related disorders. 1997 Eur J Gastroenterol Hepatol pmid:9160212
Garrison MW et al. Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against Haemophilus influenzae using an in vitro pharmacodynamic model. 1997 Diagn. Microbiol. Infect. Dis. pmid:9154410
Rodrigues AD et al. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. 1997 Drug Metab. Dispos. pmid:9152603
Chaisson RE et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. 1997 AIDS pmid:9147422
Peterson WL The role of antisecretory drugs in the treatment of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9146787
Spinzi G et al. Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9146769
Lounis N et al. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. 1997 Antimicrob. Agents Chemother. pmid:9145892
Collins L and Franzblau SG Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. 1997 Antimicrob. Agents Chemother. pmid:9145860
Khan AA et al. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. 1997 Antimicrob. Agents Chemother. pmid:9145840
Plemmons RM et al. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. 1997 Clin. Infect. Dis. pmid:9142810
Guillemet C et al. [Clarithromycin-digoxin: an unrecognized interaction in some patients]. 1997 Presse Med pmid:9137381
Spicer ST et al. The mechanism of cyclosporine toxicity induced by clarithromycin. 1997 Br J Clin Pharmacol pmid:9131953
[Management of atypical Mycobacterium infections in AIDS-patients]. 1996 Internist (Berl) pmid:9131082
Stone GG et al. PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin. 1997 Epidemiol. Infect. pmid:9129588
Lazzaroni M et al. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. 1997 Am. J. Gastroenterol. pmid:9128316
Hultén K et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. 1996 Antimicrob. Agents Chemother. pmid:9124830
Cadranel JF et al. [Acute symptomatic cytolytic hepatitis probably related to clarithromycin]. 1996 Gastroenterol. Clin. Biol. pmid:9119179
Rodrigo Sáez L et al. [The efficacy of using a short course of 6-day duration (OCA-6) in the treatment to eradicate Helicobacter pylori infection. Omeprazole, clarithromycin, amoxicillin]. 1997 Rev Esp Enferm Dig pmid:9115827
Tarlow MJ et al. Future indications for macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109159
Block SL Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. 1997 Pediatr. Infect. Dis. J. pmid:9109158
Tarlow MJ Macrolides in the management of streptococcal pharyngitis/tonsillitis. 1997 Pediatr. Infect. Dis. J. pmid:9109157
Nightingale CH Pharmacokinetics and pharmacodynamics of newer macrolides. 1997 Pediatr. Infect. Dis. J. pmid:9109156
McCracken GH Microbiologic activity of the newer macrolide antibiotics. 1997 Pediatr. Infect. Dis. J. pmid:9109155
Klein JO History of macrolide use in pediatrics. 1997 Pediatr. Infect. Dis. J. pmid:9109154
Arguedas A et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. 1997 J Chemother pmid:9106017
Fietta A et al. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. 1997 J Chemother pmid:9106014
Fietta A et al. Inhibition of intracellular growth of Staphylococcus aureus by exposure of infected human monocytes to clarithromycin and azithromycin. 1997 J Chemother pmid:9106013
Szczebara F et al. Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9105846
Kato A [Effect of erythromycin and clarithromycin on ion transport across dissected canine tracheal epithelium]. 1997 Nippon Jibiinkoka Gakkai Kaiho pmid:9103848